Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS: NWBO · Delayed Price · USD
0.388
0.00 (0.08%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Northwest Biotherapeutics Revenue
Northwest Biotherapeutics had revenue of $1.34M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $284.00K. In the year 2023, Northwest Biotherapeutics had annual revenue of $1.93M with 14.80% growth.
Revenue (ttm)
$1.34M
Revenue Growth
-38.15%
P/S Ratio
351.21
Revenue / Employee
$53,440
Employees
25
Market Cap
469.22M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.93M | 249.00K | 14.80% |
Dec 31, 2022 | 1.68M | 678.00K | 67.46% |
Dec 31, 2021 | 1.01M | -286.00K | -22.15% |
Dec 31, 2020 | 1.29M | -1.12M | -46.43% |
Dec 31, 2019 | 2.41M | 2.00M | 484.95% |
Dec 31, 2018 | 412.00K | 76.00K | 22.62% |
Dec 31, 2017 | 336.00K | -287.00K | -46.07% |
Dec 31, 2016 | 623.00K | -1.12M | -64.17% |
Dec 31, 2015 | 1.74M | 285.00K | 19.60% |
Dec 31, 2014 | 1.45M | 645.00K | 79.73% |
Dec 31, 2013 | 809.00K | 37.00K | 4.79% |
Dec 31, 2012 | 772.00K | 762.00K | 7,620.00% |
Dec 31, 2011 | 10.00K | - | - |
Dec 31, 2010 | 10.00K | - | - |
Dec 31, 2009 | 10.00K | - | - |
Dec 31, 2008 | 10.00K | - | - |
Dec 31, 2007 | 10.00K | -790.00K | -98.75% |
Dec 31, 2006 | 800.00K | 676.00K | 545.16% |
Dec 31, 2005 | 124.00K | -266.00K | -68.21% |
Dec 31, 2004 | 390.00K | -139.00K | -26.28% |
Dec 31, 2003 | 529.00K | 520.00K | 5,777.78% |
Dec 31, 2002 | 9.00K | -120.45K | -93.05% |
Dec 31, 2001 | 129.45K | -26.52K | -17.00% |
Dec 31, 2000 | 155.96K | -54.04K | -25.73% |
Dec 31, 1999 | 210.00K | -180.00K | -46.15% |
Dec 31, 1998 | 390.00K | -90.00K | -18.75% |
Dec 31, 1997 | 480.00K | 250.00K | 108.70% |
Dec 31, 1996 | 230.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Eli Lilly | 35.93B |
NWBO News
- 18 days ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 4 weeks ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire
- 4 months ago - Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PRNewsWire
- 5 months ago - Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification - PRNewsWire
- 7 months ago - Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma - PRNewsWire
- 8 months ago - Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application - PRNewsWire
- 10 months ago - Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application - PRNewsWire
- 11 months ago - Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board - PRNewsWire